Colinz Laboratories has notified BSE that it is exempt from filing the Annual Secretarial Compliance Report under SEBI regulations for the financial year ended 31st March, 2026. The company submitted its exemption notice on 3rd April, 2026, citing specific regulatory provisions that make the compliance requirement non-applicable.

Regulatory Exemption Details

The company is claiming exemption under Regulation 15(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation provides relief to smaller listed entities from certain corporate governance requirements based on their financial size.

Applicable Regulations and Circulars

The exemption relates to the Annual Secretarial Compliance Report requirement under Regulation 24A of SEBI (LODR) Regulations, 2015. The notification references multiple regulatory circulars that govern this compliance requirement:

• SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019
• BSE Circular No. LIST/COMP/10/2019-20 dated 9th May, 2019
• BSE Circular No. LIST/COMP/12/2019-20 dated 14th May, 2019

Company Information

The notification was signed by Vijaya Mani, Director of Colinz Laboratories, bearing DIN 11363910. The company operates under CIN L24200MH1986PLC041128 and trades on BSE under code 531210.

The exemption allows the company to avoid the mandatory Annual Secretarial Compliance Report filing, which is typically required for larger listed entities under SEBI's corporate governance framework. This regulatory relief is designed to reduce compliance burden on smaller companies while maintaining appropriate oversight mechanisms.

Colinz Laboratories Limited has formally notified BSE that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's regulatory framework. The pharmaceutical company submitted its confirmation regarding its status under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

SEBI Large Corporate Framework Compliance

The company confirmed that it does not fulfill the criteria specified in Para 2.2 of the SEBI circular related to the applicability of the framework for Large Corporates. This circular pertains to fund raising by issuance of debt securities by large entities and establishes specific thresholds and requirements for companies classified under this category.

Regulatory Disclosure Exemption

Since Colinz Laboratories does not meet the Large Corporate classification criteria, the company will be exempt from specific regulatory filing requirements. The exemption applies to both initial and annual disclosures mandated under the SEBI circular for the financial year ended March 31, 2026.

The confirmation eliminates the company's obligation to comply with enhanced disclosure norms and additional regulatory requirements typically imposed on entities classified as Large Corporates under the SEBI framework.

Official Authorization

The regulatory confirmation was officially authorized by key company officials. Director Vijaya Mani, holding DIN 11363910, and Chief Financial Officer Ganesh Chitte jointly signed the communication to BSE. The document bears the official company stamp, ensuring proper authentication of the regulatory submission.

The company requested BSE to take the confirmation on record, completing the necessary regulatory communication process for the financial year 2026.